Among patients with PD-1/PD-L1 inhibitor–related PNS, those with risk-antibody positivity had worse prognoses, while patients with unknown-risk antibodies had outcomes similar to those with antibody negativity, suggesting that unknown-risk antibodies are not directly pathogenic or may elicit weaker immune responses. This evidence concerns the gene PDCD1 and paraneoplastic neurologic syndrome.